Brigham and Women’s Hospital, renowned for excellence in patient care, research, and teaching, traces its roots in medicine back to 1832

The appointment of Jeffrey Clark, MD (MGH) as medical director of Clinical Trials Operations at DF/HCC became official about two months ago, but the helm is hardly new to him

When investigators went hunting for a gene implicated in Wilms’ tumor – the most common pediatric kidney cancer – they found it in an unlikely spot

Much like Houdini, who freed himself from handcuffs and shackles, tumors find clever routes of escape from VEGF receptor inhibitors, a new class of drugs heralded for prolonging the survival of patients with renal cell carcinoma (RCC), the most common kidney cancer. In recent months, a team of DF/HCC investigators has been studying these angiogenic escape mechanisms and searching for new therapies to circumvent them

Thirty-eight individuals from our seven member institutions have recently joined DF/HCC

Today we know that “smart” drugs such as Gleevec can block some of the abnormal genetic pathways that cause cancer, with little damage to normal cells